Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAMA BALARAMAN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1396709424
CMS profile
154127
Location
OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$11,349.50

199 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $6,357.50 5
Food and Beverage $3,600.92 180
Travel and Lodging $537.84 4
Education $519.92 6
Long term medical supply or device loan $333.32 4

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Astellas Pharma US Inc $2,235.89 11
Novartis Pharmaceuticals Corporation $2,042.53 14
BeiGene USA, Inc. $1,896.66 3
Alexion Pharmaceuticals, Inc. $1,040.00 1
Rigel Pharmaceuticals, Inc. $455.63 6
Janssen Biotech, Inc. $379.17 19
Pharmacosmos Therapeutics Inc. $344.66 4
Seagen Inc. $323.31 13
EISAI INC. $244.48 14
E.R. Squibb & Sons, L.L.C. $233.07 6
AstraZeneca Pharmaceuticals LP $203.42 8
Amgen Inc. $183.00 9
Incyte Corporation $159.51 7
JAZZ PHARMACEUTICALS INC. $123.36 5
GlaxoSmithKline, LLC. $110.78 6
Genentech USA, Inc. $104.93 6
Merck Sharp & Dohme LLC $101.45 5
Daiichi Sankyo Inc. $95.33 5
Heron Therapeutics, Inc. $77.42 6
Pharmacyclics LLC, an AbbVie Company $66.49 3
G1 Therapeutics, Inc. $59.57 3
Gilead Sciences, Inc. $59.56 3
PFIZER INC. $59.21 3
Karyopharm Therapeutics Inc. $58.94 3
TG Therapeutics, Inc. $45.78 2
Celgene Corporation $44.96 3
Apellis Pharmaceuticals, Inc. $44.10 2
Janssen Scientific Affairs, LLC $38.78 1
GE HealthCare $38.65 2
Lilly USA, LLC $36.92 2
GENZYME CORPORATION $33.27 2
Coherus Biosciences Inc. $31.82 1
ARRAY BIOPHARMA INC $30.06 2
Taiho Oncology, Inc. $28.51 1
CSL Behring $26.56 1
PUMA BIOTECHNOLOGY, INC. $25.54 1
PharmaEssentia USA Corporation $22.93 1
Takeda Pharmaceuticals U.S.A., Inc. $21.33 1
Medtronic, Inc. $19.58 1
MorphoSys, US Inc. $19.33 1
Kite Pharma, Inc. $19.28 1
ABBVIE INC. $18.96 1
Regeneron Healthcare Solutions, Inc. $18.78 1
Emmaus Medical, Inc. $17.13 1
Octapharma USA, Inc. $14.99 1
EMD Serono, Inc. $14.50 1
Acrotech Biopharma LLC $13.80 1
AVEO Pharmaceuticals, Inc. $13.53 1
Blueprint Medicines Corporation $13.51 1
Epizyme, Inc., $13.07 1
Ipsen Biopharmaceuticals, Inc $13.02 1
Bayer HealthCare Pharmaceuticals Inc. $12.44 1

Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAMA BALARAMAN

NPI 1396709424 · CMS profile ID 154127

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396709424?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAMA BALARAMAN, NPI 1396709424, CMS profile ID 154127. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396709424?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). RAMA BALARAMAN, NPI 1396709424, CMS profile ID 154127. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396709424?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
RAMA BALARAMAN, NPI 1396709424, CMS profile ID 154127, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1396709424?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

199 matching records · $11,349.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 199 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 199.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $20.4409/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915288689 CMS
Heron Therapeutics, Inc. $9.2608/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910503101 CMS
AstraZeneca Pharmaceuticals LP $74.9908/30/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914846291 CMS
EISAI INC. $14.4408/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908077617 CMS
Heron Therapeutics, Inc. $10.9008/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910503149 CMS
Janssen Biotech, Inc. $22.0208/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964348279 CMS
Amgen Inc. $25.1508/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939569209 CMS
Daiichi Sankyo Inc. $20.7008/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930818399 CMS
Novartis Pharmaceuticals Corporation $12.4308/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893516471 CMS
Amgen Inc. $21.8608/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939569203 CMS
Genentech USA, Inc. $14.8608/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950739477 CMS
Alexion Pharmaceuticals, Inc. $1,040.0008/10/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915412331 CMS
Seagen Inc. $13.5808/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904105813 CMS
Novartis Pharmaceuticals Corporation $6.5608/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893516467 CMS
Novartis Pharmaceuticals Corporation $14.4208/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893516469 CMS
GlaxoSmithKline, LLC. $20.7708/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944309579 CMS
Janssen Scientific Affairs, LLC $38.7808/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887199087 CMS
Seagen Inc. $99.9908/03/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904105825 CMS
Gilead Sciences, Inc. $22.3908/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929570517 CMS
Kite Pharma, Inc. $19.2808/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920063401 CMS
Novartis Pharmaceuticals Corporation $1,575.0007/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893516459 CMS
Astellas Pharma US Inc $54.9907/27/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940234733 CMS
Merck Sharp & Dohme LLC $22.3007/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944191901 CMS
Daiichi Sankyo Inc. $18.5507/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930853425 CMS
Astellas Pharma US Inc $16.6707/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940231861 CMS
Regeneron Healthcare Solutions, Inc. $18.7807/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927102717 CMS
Seagen Inc. $21.8507/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904105797 CMS
Heron Therapeutics, Inc. $14.4207/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910505415 CMS
Incyte Corporation $95.0007/07/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943014403 CMS
Janssen Biotech, Inc. $25.0007/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885716583 CMS
Janssen Biotech, Inc. $37.0307/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885716595 CMS
Merck Sharp & Dohme LLC $21.9207/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944192035 CMS
Amgen Inc. $18.7907/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939997913 CMS
E.R. Squibb & Sons, L.L.C. $22.0706/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932715529 CMS
GE HealthCare $17.7706/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953422857 CMS
Seagen Inc. $41.7706/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904105815 CMS
GlaxoSmithKline, LLC. $15.3306/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944309589 CMS
Novartis Pharmaceuticals Corporation $17.8206/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893516465 CMS
Novartis Pharmaceuticals Corporation $14.0006/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893516463 CMS
Janssen Biotech, Inc. $24.9906/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885716631 CMS
Astellas Pharma US Inc $13.4206/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940209710 CMS
E.R. Squibb & Sons, L.L.C. $22.0406/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932715527 CMS
E.R. Squibb & Sons, L.L.C. $121.2006/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932715535 CMS
Novartis Pharmaceuticals Corporation $83.3306/15/2022 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893516481 CMS
Genentech USA, Inc. $17.8506/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950766839 CMS
Novartis Pharmaceuticals Corporation $18.8606/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893516477 CMS
Merck Sharp & Dohme LLC $21.0806/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944301457 CMS
Rigel Pharmaceuticals, Inc. $44.9906/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962277141 CMS
Rigel Pharmaceuticals, Inc. $358.0706/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962277155 CMS
EISAI INC. $24.0206/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908077629 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,610.31 190
PY2020 $20,057.76 104
PY2021 $17,030.22 196
PY2022 $11,349.50 199
PY2023 $14,864.81 165
PY2024 $5,716.54 164
PY2025 $15,531.08 149

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,663.72 2
PY2025 Principal investigator $733,990.68 59
PY2024 Principal investigator $505,687.74 25
PY2023 Recipient $1,082.54 6
PY2023 Principal investigator $774,093.61 33
PY2022 Principal investigator $1,208,600.24 8
PY2021 Principal investigator $2,186,697.99 10
PY2020 Principal investigator $1,227,327.22 12
PY2019 Principal investigator $610,055.01 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

61 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $20,955.56 11/05/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER PL
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (SEZanne) No dispute reported 06/30/2026 1202523093
Principal investigator 1 BeOne Medicines Ltd. $4,258.00 10/20/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190329259
Principal investigator 1 BeOne Medicines Ltd. $2,025.00 10/20/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190329309
Principal investigator 1 BeOne Medicines Ltd. $2,025.00 10/20/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190341591
Principal investigator 1 BeOne Medicines Ltd. $2,228.00 10/20/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190341615
Principal investigator 1 Genmab U.S., Inc. $1,437.75 10/14/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932592
Principal investigator 1 BeOne Medicines Ltd. $2,250.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327031
Principal investigator 1 BeOne Medicines Ltd. $3,000.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327055
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327065
Principal investigator 1 BeOne Medicines Ltd. $4,500.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327071
Principal investigator 1 BeOne Medicines Ltd. $1,800.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327085
Principal investigator 1 BeOne Medicines Ltd. $1,250.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327107
Principal investigator 1 BeOne Medicines Ltd. $23,100.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327221
Principal investigator 1 BeOne Medicines Ltd. $14,400.00 09/30/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327287
Principal investigator 1 BeOne Medicines Ltd. $6,245.00 09/24/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327053
Principal investigator 1 BeOne Medicines Ltd. $2,498.00 09/24/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327239
Principal investigator 1 Genmab U.S., Inc. $24,030.00 08/04/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932581
Principal investigator 1 BeOne Medicines Ltd. $3,510.00 07/25/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327037
Principal investigator 1 BeOne Medicines Ltd. $2,025.00 07/25/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327049
Principal investigator 1 BeOne Medicines Ltd. $2,025.00 07/25/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327093
Principal investigator 1 BeOne Medicines Ltd. $2,228.00 07/25/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327271
Principal investigator 1 BeOne Medicines Ltd. $4,258.00 07/25/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331779
Principal investigator 1 Genmab U.S., Inc. $26,400.00 07/25/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932585
Principal investigator 1 Genmab U.S., Inc. $24,030.00 07/25/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932588
Principal investigator 1 GlaxoSmithKline, LLC. $2,025.00 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150069
Principal investigator 1 GlaxoSmithKline, LLC. $4,050.00 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150074
Principal investigator 1 GlaxoSmithKline, LLC. $18,900.00 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150078
Principal investigator 1 GlaxoSmithKline, LLC. $2,430.00 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150082
Principal investigator 1 GlaxoSmithKline, LLC. $1,350.00 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150088
Principal investigator 1 GlaxoSmithKline, LLC. $1,012.50 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154944
Principal investigator 1 GlaxoSmithKline, LLC. $1,350.00 07/25/2025 Non-covered Recipient Entity
FLORIDA UROLOGY PARTNERS LLC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154948
Principal investigator 1 BeOne Medicines Ltd. $3,033.00 07/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190327285
Principal investigator 1 Genmab U.S., Inc. $55,890.00 06/05/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932560
Principal investigator 1 Genmab U.S., Inc. $4,580.25 06/05/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932564
Principal investigator 1 Genmab U.S., Inc. $12,015.00 06/05/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932568
Principal investigator 1 Genmab U.S., Inc. $14,715.00 06/05/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932576
Principal investigator 1 Genmab U.S., Inc. $7,039.92 05/28/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932556
Principal investigator 1 BeiGene, Ltd. $3,498.00 05/16/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320700
Principal investigator 1 BeiGene, Ltd. $3,498.00 05/16/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325646
Principal investigator 1 BeiGene, Ltd. $8,100.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320792
Principal investigator 1 BeiGene, Ltd. $8,912.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190322888
Principal investigator 1 BeiGene, Ltd. $10,125.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325040
Principal investigator 1 BeiGene, Ltd. $3,510.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325048
Principal investigator 1 BeiGene, Ltd. $11,140.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325604
Principal investigator 1 BeiGene, Ltd. $10,125.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325620
Principal investigator 1 BeiGene, Ltd. $8,100.00 05/09/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325634
Principal investigator 1 ABBVIE INC. $20,000.00 05/07/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER PL
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202483349
Principal investigator 1 BeiGene, Ltd. $3,498.00 04/25/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325016
Principal investigator 1 Genmab U.S., Inc. $17,921.68 04/24/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932572
Principal investigator 1 Mirati Therapeutics, Inc. $887.50 04/02/2025 Non-covered Recipient Entity
Ocala Oncology Center, Pl
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther No dispute reported 06/30/2026 1236530873
Recipient Novartis Pharmaceuticals Corporation $1,355.30 04/01/2025 Covered Recipient Physician CLEE011A2207 No dispute reported 06/30/2026 1190292827
Principal investigator 1 AstraZeneca Pharmaceuticals LP $61,263.92 03/24/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER PL
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185550183
Principal investigator 1 Genmab U.S., Inc. $28,300.00 03/20/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932552
Principal investigator 1 Merck Sharp & Dohme LLC $157,600.00 03/18/2025 Non-covered Recipient Entity
Ocala Oncology Center
An Open-Label Phase 1a,1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1232932637
Recipient GlaxoSmithKline, LLC. $308.42 03/14/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154952
Principal investigator 1 BeiGene, Ltd. $3,498.00 03/12/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190319988
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,300.00 02/25/2025 Non-covered Recipient Entity
OCALA ONCOLOGY CENTER PL
Clinical trial to assess the efficacy and safety of an alternative dosing regimen of ribociclib in breast cancer No dispute reported 06/30/2026 1190310040
Principal investigator 1 BeiGene, Ltd. $3,498.00 02/21/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320018
Principal investigator 1 BeiGene, Ltd. $3,498.00 02/21/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324294
Principal investigator 1 Genmab U.S., Inc. $43,850.60 01/30/2025 Non-covered Recipient Entity
OCALA ONCOLOGY OCALA MAIN
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235932548
Principal investigator 1 BeiGene, Ltd. $3,498.00 01/29/2025 Non-covered Recipient Entity
Ocala Oncology Center PL
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190324634